Clinical Trials Browser

INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × Fluorouracil × Clear all

NCT06469944 2026-03-16

MK-3475-06C

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05152147 2026-02-27

HERIZON-GEA-01

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT04949256 2025-12-15

MK-7902-014

Phase 3 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT03374254 2024-11-21

KEYNOTE-651

Phase 1 Completed

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04210115 2024-11-15

KEYNOTE 975

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03189719 2024-10-15

KEYNOTE-590

Phase 3 Completed

749 enrolled 40 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02494583 2023-04-13

MK-3475-062

Phase 3 Completed

763 enrolled 29 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

Phase 2 Completed

318 enrolled 24 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Phase 3 Withdrawn

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms